This is where other indications play an important role - yet we, as shareholders, are in the dark. Anyone have a poll in place to guess when the ASM list of questions will be answered? Perhaps, if they haven't addressed yet, we can add a few more around ATHENA now.
No two ways about it this is bad news for the shares. However, I believe this trial will resume. though I won't speculate on when. We don't even know if the affected patients were treated with ADRCs or the placebo. Time to change the phrase "Murphy's Law" to "Cytori's Law".